Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies (DVAX) reported a record total revenue of $439.4 million for 2021, a significant rise from $46.6 million in 2020. Key revenue drivers included HEPLISAV-B with $61.9 million and CpG 1018 adjuvant supply generating $375.2 million. The company anticipates at least $550 million in CpG 1018 revenue in 2022. Dynavax ended the year with approximately $546 million in cash. Positive momentum is expected with new clinical developments and increased market share opportunities stemming from CDC recommendations. Net income reached $76.7 million, marking a profitable year.
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:50 p.m. E.T. The chat will feature Ryan Spencer, CEO, and Kelly MacDonald, CFO. Interested parties can access the presentation via the 'Events & Presentations' page on the company's website. Dynavax is known for developing HEPLISAV-B®, a Hepatitis B vaccine, and is advancing its CpG 1018 adjuvant for various infectious diseases.
Dynavax Technologies (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and live audio webcast will follow at 4:30 p.m. ET. The company focuses on developing innovative vaccines, including its approved hepatitis B vaccine, HEPLISAV-B. Dynavax is also advancing its CpG 1018 adjuvant for various infectious diseases and collaborating on vaccines for COVID-19 and other diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced on February 2, 2022, the granting of nonstatutory stock options for 105,000 shares and restricted stock units (RSUs) covering 73,250 shares to 11 new employees. The stock options were priced at $12.65 per share, aligning with the market close on the grant date. Each option has a seven-year term and a three-year vesting schedule. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the 2021 Inducement Award Plan, aimed at incentivizing new hires as the company advances its vaccine development initiatives.
Dynavax Technologies Corporation (Nasdaq: DVAX) outlined its strategic priorities for 2022 and introduced a new herpes zoster (shingles) vaccine candidate. Anticipating profitability, the company expects continued revenue growth from its HEPLISAV-B hepatitis B vaccine and CpG 1018 adjuvant supply for COVID-19 vaccines. The CDC's recent recommendations for HEPLISAV-B could expand its market opportunity to $800 million by 2027. Additionally, the global clinical trial for the shingles vaccine aims to demonstrate safety and immunogenicity, with results expected by the end of 2022.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 94,000 shares and restricted stock units (RSUs) for 2,500 shares to 5 newly-hired employees. The stock options were awarded on January 4, 2022, at an exercise price of $13.40, matching the closing stock price on that date. The stock options have a 7-year term and follow a vesting schedule of one-third after one year and the remainder monthly over two years. The RSUs will vest one-third annually. These grants were made to comply with Nasdaq Listing Rule 5635(c)(4).
Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2022 Conference scheduled for January 10-13, 2022. The on-demand presentation will be accessible starting January 10, 2022, at 7:00 a.m. E.T. on the company’s website under the 'Events & Presentations' section. Dynavax is a biopharmaceutical firm specializing in developing vaccines, including HEPLISAV-B®, which is approved for preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (DVAX) announced that Biological E's COVID-19 vaccine, CORBEVAX™, received emergency use approval from India's Drugs Controller General. This vaccine uses Dynavax's CpG 1018® adjuvant. The companies have a commercial supply agreement for 300 million doses, bolstering Dynavax's supply capabilities for 2022 and beyond. The CpG 1018 adjuvant is proven to enhance vaccine immune response and is included in multiple vaccines, contributing over $197 million in revenue in 2021.
Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on
Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Elaine Sun to its Board of Directors. Ms. Sun, who brings over 20 years of experience in life sciences and investment banking, has previously held significant roles at Halozyme and SutroVax. CEO Ryan Spencer expressed confidence in her expertise to enhance Dynavax's strategic direction, particularly in expanding HEPLISAV-B market share and advancing their CpG 1018 adjuvant development. The announcement highlights Dynavax's commitment to innovative vaccine solutions against infectious diseases.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
